BioCentury | Sep 11, 2006
Strategy

Biotech accumulators

...is relatively new ground for Santhera, which was created in 2004 through the merger of MyoContract AG...
BioCentury | Jan 9, 2006
Strategy

Working through the checklist

...Switzerland) was created in 2004 through the merger of Graffinity Pharmaceuticals AG (Heidelberg, Germany) and MyoContract AG...
...business based on a small molecule fragment-based technology called RAISE (Rapid affinity instructed structural evolution). MyoContract...
...idebenone as a dementia treatment in Japan, but the product was withdrawn on efficacy grounds. MyoContract...
BioCentury | Jan 9, 2006
Company News

Santhera Pharmaceuticals AG supply/service news

...from the newco. Santhera was formed through the 2004 merger of Graffinity Pharmaceuticals AG and MyoContract AG...
BioCentury | Jan 4, 2006
Company News

Santhera spins out Graffinity

...Sixteen months after it was formed through the merger of Graffinity and MyoContract , Santhera (Liestal...
BioCentury | Jun 27, 2005
Product Development

Insulin rush

...AG (Liestal, Switzerland), which was formed through the 2004 merger of Graffinity Pharmaceuticals AG and MyoContract AG...
BioCentury | Dec 17, 2004
Financial News

Santhera raises EUR 7 million

...the company's board. Santhera was created through the August merger of Graffinity (Heidelberg, Germany) and MyoContract...
BioCentury | Oct 4, 2004
Finance

Europe: The news will be light

...functional genomics and metabolic company Graffinity Pharmaceuticals AG (Heidelberg, Germany) and musculoskeletal and metabolic company MyoContract AG...
BioCentury | Sep 13, 2004
Company News

Graffinity Pharmaceuticals AG, MyoContract deal

...company Graffinity merged in a stock deal of undisclosed value with musculoskeletal and metabolic company MyoContract...
...preclinical programs, including a dipeptidyl-peptidase-4 ( DPP-4 ) inhibitor program to treat Type II diabetes. MyoContract...
...Meier, founder and CEO of MyoContract, is now CSO. Graffinity Pharmaceuticals AG , Heidelberg, Germany MyoContract AG...
BioCentury | Sep 13, 2004
Strategy

Value chain filling

...pipeline in metabolic indications, with MyoContract's late-stage clinical program and preclinical pipeline in musculoskeletal therapies. MyoContract...
...an orphan drug indication, with published efficacy data," said Thomas Meier, founder and CEO of MyoContract...
...to do this fast enough via organic growth. MyoContract (Liestal, Switzerland) has both. "On the MyoContract...
BioCentury | Sep 8, 2004
Company News

Graffinity merges with MyoContract

...company Graffinity (Heidelberg, Germany) merged in an all share deal with musculoskeletal and metabolic company MyoContract...
...a fee-for-service basis, and two preclinical programs including a DPP-IV inhibitor program to treat diabetes. MyoContract...
...neuromuscular disease. The compound is expected to enter Phase III studies by early next year. MyoContract...
Items per page:
1 - 10 of 14
BioCentury | Sep 11, 2006
Strategy

Biotech accumulators

...is relatively new ground for Santhera, which was created in 2004 through the merger of MyoContract AG...
BioCentury | Jan 9, 2006
Strategy

Working through the checklist

...Switzerland) was created in 2004 through the merger of Graffinity Pharmaceuticals AG (Heidelberg, Germany) and MyoContract AG...
...business based on a small molecule fragment-based technology called RAISE (Rapid affinity instructed structural evolution). MyoContract...
...idebenone as a dementia treatment in Japan, but the product was withdrawn on efficacy grounds. MyoContract...
BioCentury | Jan 9, 2006
Company News

Santhera Pharmaceuticals AG supply/service news

...from the newco. Santhera was formed through the 2004 merger of Graffinity Pharmaceuticals AG and MyoContract AG...
BioCentury | Jan 4, 2006
Company News

Santhera spins out Graffinity

...Sixteen months after it was formed through the merger of Graffinity and MyoContract , Santhera (Liestal...
BioCentury | Jun 27, 2005
Product Development

Insulin rush

...AG (Liestal, Switzerland), which was formed through the 2004 merger of Graffinity Pharmaceuticals AG and MyoContract AG...
BioCentury | Dec 17, 2004
Financial News

Santhera raises EUR 7 million

...the company's board. Santhera was created through the August merger of Graffinity (Heidelberg, Germany) and MyoContract...
BioCentury | Oct 4, 2004
Finance

Europe: The news will be light

...functional genomics and metabolic company Graffinity Pharmaceuticals AG (Heidelberg, Germany) and musculoskeletal and metabolic company MyoContract AG...
BioCentury | Sep 13, 2004
Company News

Graffinity Pharmaceuticals AG, MyoContract deal

...company Graffinity merged in a stock deal of undisclosed value with musculoskeletal and metabolic company MyoContract...
...preclinical programs, including a dipeptidyl-peptidase-4 ( DPP-4 ) inhibitor program to treat Type II diabetes. MyoContract...
...Meier, founder and CEO of MyoContract, is now CSO. Graffinity Pharmaceuticals AG , Heidelberg, Germany MyoContract AG...
BioCentury | Sep 13, 2004
Strategy

Value chain filling

...pipeline in metabolic indications, with MyoContract's late-stage clinical program and preclinical pipeline in musculoskeletal therapies. MyoContract...
...an orphan drug indication, with published efficacy data," said Thomas Meier, founder and CEO of MyoContract...
...to do this fast enough via organic growth. MyoContract (Liestal, Switzerland) has both. "On the MyoContract...
BioCentury | Sep 8, 2004
Company News

Graffinity merges with MyoContract

...company Graffinity (Heidelberg, Germany) merged in an all share deal with musculoskeletal and metabolic company MyoContract...
...a fee-for-service basis, and two preclinical programs including a DPP-IV inhibitor program to treat diabetes. MyoContract...
...neuromuscular disease. The compound is expected to enter Phase III studies by early next year. MyoContract...
Items per page:
1 - 10 of 14